Bayer: Xarelto and Eylea to reach peak revenues in 5-6 years


Bayer believes that Xarelto (blood thinner) and Eylea (eye), which is developed by Regeneron (REGN), will hit peak revenues in 5-6 years. Bayer holds the license to sell Eylea outside the U.S.

Bayer has increased its combined peak annual sales forecast for its five most important drugs - Adempas (lung), Stivarga (cancer) and Xofigo (cancer), as well as Eylea and Xarelto - to at least €7.5B from a prior forecast of €5.5B. The treatments generated sales of €1.52B in 2013.

See Bayer's earnings

From other sites
Comments (1)
  • toosmarttofail
    , contributor
    Comments (697) | Send Message
     
    Eylea slows the progression of wet macular degeneration; ACTC's Phase I drug is already *curing* it.

     

    When ACTC publishes its findings, Eylea will be a dead drug walking. Obsolete. A Dinosaur. The question is, does this make REGN the "short of the century" or does REGN buy out ACTC while they still can?
    28 Feb 2014, 08:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs